Yili Chuanning Biotechnology Co.,Ltd.

Informe acción SZSE:301301

Capitalización de mercado: CN¥32.2b

Yili Chuanning BiotechnologyLtd Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Yili Chuanning BiotechnologyLtd has been growing earnings at an average annual rate of 47.4%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 12.9% per year. Yili Chuanning BiotechnologyLtd's return on equity is 18.1%, and it has net margins of 24.2%.

Información clave

47.4%

Tasa de crecimiento de los beneficios

53.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 11.3%
Tasa de crecimiento de los ingresos12.9%
Rentabilidad financiera18.1%
Margen neto24.2%
Última actualización de beneficios30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

Oct 11
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely

If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

Jul 23
If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity

We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

May 31
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease

Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Feb 26
Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt

Desglose de ingresos y gastos

Cómo gana y gasta dinero Yili Chuanning BiotechnologyLtd. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

SZSE:301301 Ingresos, gastos y beneficios (CNY Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 245,6981,37618960
30 Jun 245,6021,31618360
31 Mar 245,0771,11817658
31 Dec 234,82394117255
30 Sep 234,4627197048
30 Jun 234,2545658441
31 Mar 234,09348613539
01 Jan 233,82141217035
30 Sep 223,63427235059
31 Mar 223,34515417135
01 Jan 223,23211112933
31 Dec 203,64922912325
31 Dec 193,1439117818
31 Dec 183,3493901235

Ingresos de calidad: 301301 has high quality earnings.

Margen de beneficios creciente: 301301's current net profit margins (24.2%) are higher than last year (16.1%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 301301's earnings have grown significantly by 47.4% per year over the past 5 years.

Acelerando crecimiento: 301301's earnings growth over the past year (91.3%) exceeds its 5-year average (47.4% per year).

Beneficios vs. Industria: 301301 earnings growth over the past year (91.3%) exceeded the Biotechs industry 0.08%.


Rentabilidad financiera

Alta ROE: 301301's Return on Equity (18.1%) is considered low.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado